Hospira Can't Void Amgen's $70M Biosimilar Patent Win
A Delaware federal judge on Monday refused to erase a $70 million patent infringement verdict against Hospira Inc. over its biosimilar version of Amgen Inc.'s anemia treatment Epogen, saying a jury...To view the full article, register now.
Already a subscriber? Click here to view full article